ライフサイエンスコーパス: expanded disability status scale

1 Auditory Serial Addition Test-3 [PASAT], and Expanded Disability Status Scale).

2 r correlated with disability measured on the Expanded Disability Status Scale.

3 ing-remitting MS and mild disability (EDSS - Expanded Disability Status Scale 1-3.5) and 16 control s

4 ntion-to-treat analysis of time to 1- (entry expanded disability status scale, 3.0-5.0) or 0.5-point

5 panded disability status scale change (entry expanded disability status scale, 5.5-6.5) sustained for

6 Furthermore, 50% of CD24v/v patients with expanded disability status scale 6.0 reached the milesto

7 Clinical disability was measured with the Expanded Disability Status Scale, 9-Hole Peg Test, and 2

8 r 3 months confirmed 1-point increase on the Expanded Disability Status Scale), active magnetic reson

9 ndary endpoints were disability (measured by expanded disability status scale), ambulation (Hauser sc

10 weeks with validated measures of impairment (Expanded Disability Status Scale and Functional Systems)

11 EDSS Expanded Disability Status Scale and MSFC MS functional

12 of GM change with clinical outcome measures (Expanded Disability Status Scale and Multiple Sclerosis

13 patients and correlated positively with the Expanded Disability Status Scale at attack leading to bi

14 ths of confirmed disability worsening on the Expanded Disability Status Scale at month 12.

15 Their median Expanded Disability Status Scale at natalizumab interrup

16 n sustained for 12 weeks, as measured by the Expanded Disability Status Scale, at 2 years.

17 uation included motor and cognitive testing: Expanded Disability Status Scale, cerebellar Functional

18 sability status scale, 3.0-5.0) or 0.5-point expanded disability status scale change (entry expanded

19 d with higher disability, as assessed by the Expanded Disability Status Scale (coefficient = -0.41, 0

20 days with no measurable improvement) on the Expanded Disability Status Scale (EDSS) (range, 0-10, wi

21 tures including presenting symptoms, time to Expanded Disability Status Scale (EDSS) 4.0, 6.0 and 8.0

22 ability milestones was shorter than in ROMS (Expanded Disability Status Scale (EDSS) 4.0:8.1 vs. 17.1

23 Physical disability was assessed using the expanded disability status scale (EDSS) and motor compon

24 nds only and disability determined using the Expanded Disability Status Scale (EDSS) and Multiple Scl

25 rological examination and were scored on the Expanded Disability Status Scale (EDSS) and Multiple Scl

26 Patients had clinical [Expanded Disability Status Scale (EDSS) and Multiple Scl

27 sNfL was independently associated with Expanded Disability Status Scale (EDSS) assessments (bet

28 linical and laboratory data including serial Expanded Disability Status Scale (EDSS) assessments, fro

29 Neurologic progression defined by the expanded disability status scale (EDSS) did not increase

30 ute T2 lesion volume and either the absolute expanded disability status scale (EDSS) grade (P = .32)

31 ed relapse rate, number of relapses, time to Expanded Disability Status Scale (EDSS) progression, cha

32 d, or natalizumab), age 65 years or younger, Expanded Disability Status Scale (EDSS) score 6.5 or low

33 he intragroup relationship between WBNAA and Expanded Disability Status Scale (EDSS) score and Mann-W

34 atio (treated vs untreated) measured both in Expanded Disability Status Scale (EDSS) score and utilit

35 value and the variation from baseline of the Expanded Disability Status Scale (EDSS) score at 60 mont

36 gative correlation between brain atrophy and Expanded Disability Status Scale (EDSS) score in patient

37 efinite MS, CDMS (second attack or sustained Expanded Disability Status Scale (EDSS) score increase))

38 e participants were aged 18-55 years, had an Expanded Disability Status Scale (EDSS) score of 0-5.0,

39 sion of disability measured by change in the Expanded Disability Status Scale (EDSS) score of 1.0 or

40 t no relapse in the previous 30 days, and an Expanded Disability Status Scale (EDSS) score of 5.5 poi

41 r MS onset took the longest time to reach an Expanded Disability Status Scale (EDSS) score of 6 (mean

42 ubcutaneous interferon beta-1a, and the mean expanded disability status scale (EDSS) score of the ale

43 Mean Expanded Disability Status Scale (EDSS) score was 3.5.

44 g no relapse, no 3-month sustained change in expanded disability status scale (EDSS) score, and no ne

45 andomisation sequence, balanced according to expanded disability status scale (EDSS) score, centre, a

46 tients; 3.81 [0.13-9.47]; p=0.032), although expanded disability status scale (EDSS) scores were not

47 Expanded Disability Status Scale (EDSS) scores were unch

48 Expanded Disability Status Scale (EDSS) scores, disease

49 Median baseline expanded disability status scale (EDSS) was 7.0 (range,

50 nt, neurologic disability as measured by the Expanded Disability Status Scale (EDSS) was stable or im

51 for early disease activity predicting severe Expanded Disability Status Scale (EDSS) worsening (worst

52 te endpoint based on change from baseline in Expanded Disability Status Scale (EDSS), 25' Timed-Walk

53 1.5 T scanner and clinically assessed on the Expanded Disability Status Scale (EDSS), 9-hole peg test

54 improved by at least 1 point on the Kurtzke expanded disability status scale (EDSS), and five patien

55 d moderate or severe locomotor disabilities [Expanded Disability Status Scale (EDSS), score 3.5-8], w

56 monly used scales in multiple sclerosis, the Expanded Disability Status Scale (EDSS), the Scripps Neu

57 Disability was scored with the Expanded Disability Status Scale (EDSS), the timed 25-fo

58 d DMD exposure decreased the risk of a first Expanded Disability Status Scale (EDSS)-worsening event

59 erosis in clinical trials has been Kurtzke's expanded disability status scale (EDSS).

60 ression of at least 1.0 point on the Kurtzke Expanded Disability Status Scale (EDSS).

61 We assessed disability worsening using the Expanded Disability Status Scale (EDSS).

62 apse rate, and progression determined by the Expanded Disability Status Scale (EDSS).

63 Physical disability was measured by the Expanded Disability Status Scale (EDSS).

64 We also found miRNAs to be linked to Expanded Disability Status Scale (EDSS).

65 r) between imaging data and clinical scores (Expanded Disability Status Scale [EDSS] and MS multiple

66 ated with disability (as determined with the Expanded Disability Status Scale [EDSS] score; P = .046,

67 at was constrained by experimental data (the expanded disability status scale [EDSS] time series) obt

68 associated with clinical (conversion to MS, Expanded Disability Status Scale [EDSS]) and magnetic re

69 rain MRI, clinical relapses, and disability (Expanded Disability Status Scale [EDSS]).

70 udinal clinical course (measured by means of Expanded Disability Status Scale [EDSS]).

71 evolution (-0.23 points annually; P = .01), Expanded Disability Status Scale evolution (0.57 points

72 sociated clinical data was used to calculate expanded disability status scale for each patient preced

73 45% had significant disability (Expanded Disability Status Scale >/=6).

74 Median score on the expanded disability status scale improved from 4.3 (rang

75 included: history, neurological examination, expanded disability status scale, magnetic resonance ima

76 7.2 +/- 15 months; RRMS: 8.0 +/- 6.5 years, Expanded Disability Status Scale (median, min-max): CIS:

77 The Expanded Disability Status Scale (median; inter-quartile

78 e or relapsing-remitting multiple sclerosis (Expanded Disability Status Scale: median = 1, range = 0-

79 Outcomes included 2-year change in the Expanded Disability Status Scale, Multiple Sclerosis Fun

80 s and postural stability, in addition to the Expanded Disability Status Scale, Nine Hole Peg Test, Ti

81 ty progression was defined as an increase in Expanded Disability Status Scale of >/= 1.0 compared to

82 gnosis of 13.7+/-10 and 9.9+/-7.8 years, and Expanded Disability Status Scale of 2.6+/-2.0.

83 prognosis, ongoing disease activity, and an Expanded Disability Status Scale of 3.0-6.0.

84 ed lesion volumes (0.05 < P < 0.01) and with Expanded Disability Status Scale (P < 0.05).

85 with Scripps Neurologic Rating Score and the Expanded Disability Status Scale (p < 0.05).

86 hite matter PK11195 BPND correlated with the Expanded Disability Status Scale (P = 0.007; r = 0.672).

87 Clinical disability scores (Expanded Disability Status Scale [p = 0.009] and Institu

88 (p=0.006 and beta-coefficient=-0.67 with the Expanded Disability Status Scale; p=0.003 and beta-coeff

89 an either agent alone in lessening confirmed Expanded Disability Status Scale progression or change i

90 Expanded Disability Status Scale pyramidal score was pre

91 e appropriate Functional Scale scores of the Expanded Disability Status Scale (r = -0.50, P < 0.01).

92 GM, but not WM, fraction correlated with expanded disability status scale (r(s) = -0.48; p < 0.00

93 atients in remission (median age 43.5 years; Expanded Disability Status Scale range 1.5-6.5; 35 relap

94 Relapse rate and the Expanded Disability Status Scale remain the standard cli

95 ickness showed inverse associations with the Expanded Disability Status Scale (rho = -0.295; P = .03

96 oss in spinal cord lesions from 5 paralyzed (Expanded Disability Status Scale score > or =7.5) MS pat

97 only the spinal cord and peripheral nerves (Expanded Disability Status Scale score >/= 6).

98 k (T25FW) in clinical trial subjects with an Expanded Disability Status Scale score >/=3.5, including

99 Limited motor dysfunction (Expanded Disability Status Scale score < 6) prior to tra

100 5); P < 0.05] and maintenance of ambulation (Expanded Disability Status Scale score < 7) post-transpl

101 es in the 24 months before screening, and an Expanded Disability Status Scale score </= 5.5, were ran

102 ng multiple sclerosis (age 18-65 years, with Expanded Disability Status Scale score </=5) were random

103 ssessed using the ambulation index (AI), the Expanded Disability Status Scale score (EDSS) and the 9-

104 from first symptom to scan 1.8 years, median Expanded Disability Status Scale score 1.0).

105 transfer ratio gradient also correlated with Expanded Disability Status Scale score 5 years later (Sp

106 r ratio histogram peak height (P = .02), for Expanded Disability Status Scale score and magnetization

107 fer histogram peak height (P = .02), and for Expanded Disability Status Scale score and percentage of

108 Relapses were confirmed by an increase in Expanded Disability Status Scale score assessed by an in

109 to male ratio, 2.36; mean age, 41 years; and Expanded Disability Status Scale score at the initiation

110 ces in the annualized relapse rate ratio and Expanded Disability Status Scale score before and after

111 redictive value of 78.3% for no progression (Expanded Disability Status Scale score change </=0.5) at

112 most clinical trials rely on progression of Expanded Disability Status Scale score confirmed over 3

113 GM areas had the strongest correlation with Expanded Disability Status Scale score followed by thora

114 ndependent of age, sex, and patient-reported Expanded Disability Status Scale score in a Cox regressi

115 rate was 3.0 (range, 2.3-3.0) and the median Expanded Disability Status Scale score increased from 5.

116 The risk of reaching Expanded Disability Status Scale score milestones of 4 a

117 3.5 to 6.5 or relapsing-remitting MS and an Expanded Disability Status Scale score of 0 to 5.0.

118 ly powerful for patients with benign MS with Expanded Disability Status Scale score of 2 or lower for

119 Patients had secondary-progressive MS and an Expanded Disability Status Scale score of 3.5 to 6.5 or

120 3 mm on a T2-weighted brain MRI scan, and an Expanded Disability Status Scale score of 5.0 or lower.

121 Ten SPMS patients with a mean expanded disability status scale score of 6.3 (SD, 1.5)

122 nsisted of absence of relapses, no sustained Expanded Disability Status Scale score progression, and

123 The Expanded Disability Status Scale score remained stable f

124 Finally, the expanded disability status scale score showed a mild, po

125 e range, 0.0-0.8) (P = .008), and the median Expanded Disability Status Scale score significantly dec

126 aquaporin 4-IgG seropositive; and the median Expanded Disability Status Scale score was 4.0 (interqua

127 Annualized relapse rate (ARR), disability (Expanded Disability Status Scale score), change in anti-

128 lesion on MRI, and sustained progression of Expanded Disability Status Scale score).

129 ging, as well as MS relapses and disability (Expanded Disability Status Scale score).

130 up to 12 months predicted lower disability (Expanded Disability Status Scale score, -0.17; P = .004)

131 rable in terms of sex, age, body mass index, Expanded Disability Status Scale score, disease duration

132 Annualized relapse rate, Expanded Disability Status Scale score, spinal cord and

133 5% CI, -1.18 to -0.10) reduction in the mean Expanded Disability Status Scale score.

134 as observed between disease duration and the Expanded Disability Status Scale score.

135 atients had a sustained improvement in their Expanded Disability Status Scale score.

136 WM, and TCA) were inversely correlated with Expanded Disability Status Scale score.

137 ing parameters, annualized relapse rate, and Expanded Disability Status Scale score.

138 gG serostatus, clinical characteristics, and Expanded Disability Status Scale score.

139 inal cord area and volume, and scores on the Expanded Disability Status Scale (score range, 0 to 10;

140 ologic disability as assessed by the Kurtzke Expanded Disability Status Scale (score range, 0-10; hig

141 ent vs 0.4 with treatment; P < .001), median Expanded Disability Status Scale scores (2 without treat

142 e had a significantly lower risk of reaching Expanded Disability Status Scale scores 4 (hazard ratio:

143 al: 1.18-1.86) times higher risk of reaching Expanded Disability Status Scale scores 4 and 6 compared

144 -smokers and non-smokers in terms of time to Expanded Disability Status Scale scores 4 or 6.

145 from the onset episode, with better recovery Expanded Disability Status Scale scores and a lower risk

146 Annualised relapse rates, Expanded Disability Status Scale scores and tolerability

147 sensory cortex was associated with increased Expanded Disability Status Scale scores in surface-based

148 he general US population and correlated with Expanded Disability Status Scale scores, sustained disab

149 and grey and white matter volumes, and with expanded disability status scale scores.

150 of multiple sclerosis was determined by the Expanded Disability Status Scale, self-report version.

151 Major changes to the expanded disability status scale should be avoided to pr

152 rogression (CDP), a prespecified increase in Expanded Disability Status Scale sustained for 12 weeks.

153 olution (0.57 points annually; P = .04), and Expanded Disability Status Scale sustained progression (

154 (defined as an increase in the score on the Expanded Disability Status Scale that was sustained for

155 In the applied Expanded Disability Status Scale, the incidence rate of

156 6.0 years old, had MS for 6.1 +/- 5.8 years, Expanded Disability Status Scale was 2.2 +/- 0.8, and br

157 total relapses averaged 4 +/- 2.4, and their Expanded Disability Status Scale was 2.7 +/- 0.5.

158 At last visit, Expanded Disability Status Scale was 4.4 +/- 1.95, Multi

159 Disability status (Expanded Disability Status Scale) was recorded from reco